Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.


The antithrombotic treatment of coronary artery disease is becoming increasingly complex. Aspirin is often combined with more potent antiplatelet agents such as thienopyridines and glycoprotein IIb/IIIa inhibitors. The classic anticoagulant unfractionated heparin is giving way to low-molecular-weight heparin, the pentasaccharide fondaparinux and the direct… (More)
DOI: 10.1111/j.1538-7836.2010.03737.x


5 Figures and Tables

Slides referencing similar topics